Shilpa Medicare Surges After U.S. FDA Issues EIR

Gold Silver Reports (GSR) – Shilpa Medicare Surges After U.S. FDA Issues EIR — Shares of the Raichur-based producer and exporter of active pharmaceutical ingredients rose as much as 13 percent, the most in over 17 months, to Rs 516.

The U.S. drug regulator issued an establishment inspection report (EIR) for inspection conducted at its manufacturing unit in Telangana between Nov. 11-30, 2017. The U.S. FDA has determined that the inspection classification of this facility is VAI and accordingly issued an EIR, Shilpa Medicare said in an exchange filing.

Shilpa Medicare’s trading volume was 53.5 times its 20-day average. – Neal Bhai Reports (NBR) INDIA

Spread the love

Neal Bhai has been involved in the Bullion and Metals markets since 1998 – he has experience in many areas of the market from researching to trading and has worked in Delhi, India. Mobile No. - 9899900589 and 9582247600

Leave a Comment